Charles Schwab Investment Management Inc. Boosts Stock Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Charles Schwab Investment Management Inc. boosted its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRXFree Report) by 4.3% in the third quarter, Holdings Channel.com reports. The fund owned 1,417,295 shares of the biopharmaceutical company’s stock after acquiring an additional 58,147 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Lexicon Pharmaceuticals were worth $2,225,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Point72 Asset Management L.P. lifted its holdings in shares of Lexicon Pharmaceuticals by 605.2% in the 2nd quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company’s stock worth $6,924,000 after buying an additional 3,536,805 shares during the period. Nantahala Capital Management LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the 2nd quarter worth $3,871,000. Pinnacle Associates Ltd. lifted its holdings in shares of Lexicon Pharmaceuticals by 0.9% in the 3rd quarter. Pinnacle Associates Ltd. now owns 1,730,821 shares of the biopharmaceutical company’s stock worth $2,648,000 after buying an additional 14,990 shares during the period. Marshall Wace LLP lifted its holdings in shares of Lexicon Pharmaceuticals by 138.5% in the 2nd quarter. Marshall Wace LLP now owns 1,190,448 shares of the biopharmaceutical company’s stock worth $2,000,000 after buying an additional 691,276 shares during the period. Finally, Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Lexicon Pharmaceuticals by 34.7% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 731,138 shares of the biopharmaceutical company’s stock worth $1,148,000 after buying an additional 188,239 shares during the period. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on LXRX. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Lexicon Pharmaceuticals in a report on Wednesday, November 13th. Leerink Partners set a $6.00 target price on Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a report on Friday, October 18th. Finally, Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Friday, November 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $6.00.

View Our Latest Stock Analysis on LXRX

Lexicon Pharmaceuticals Trading Down 1.4 %

Shares of NASDAQ LXRX opened at $0.81 on Monday. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The stock has a market capitalization of $199.53 million, a P/E ratio of -1.08 and a beta of 1.07. Lexicon Pharmaceuticals, Inc. has a 1-year low of $0.62 and a 1-year high of $3.73. The business has a fifty day moving average price of $1.28 and a 200 day moving average price of $1.60.

Lexicon Pharmaceuticals (NASDAQ:LXRXGet Free Report) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The business had revenue of $1.75 million for the quarter, compared to analyst estimates of $3.14 million. During the same period in the prior year, the company earned ($0.21) earnings per share. Equities research analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.

Lexicon Pharmaceuticals Company Profile

(Free Report)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.

Recommended Stories

Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRXFree Report).

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.